1. 32 Safety, pharmacokinetics and pharmacodynamics of BI 705564, a covalent inhibitor of brutons tyrosine kinase in phase 1 clinical trials in healthy volunteers. (April 2019) Authors: Litzenburger, Tobias; Müller, Fabian; Schultz, Armin; Klein, Elliott; Ramanujam, Meera; Wu, Jing; Wiebe, Sabrina; Benediktus, Ewald; Hui, Jianan; Li, Xiujiang; Flack, Mary; Padula, Steven J; Visvanathan, Sudha; Steffgen, Jürgen; Hünnemeyer, Andreas Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial. Issue 8 (25th June 2019) Authors: Ohtsuki, Mamitaro; Fujita, Hideki; Watanabe, Mitsunori; Suzaki, Keiko; Flack, Mary; Huang, Xin; Kitamura, Susumu; Valdes, Joaquin; Igarashi, Atsuyuki Journal: Journal of dermatology Issue: Volume 46:Issue 8(2019) Page Start: 686 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Issue 10148 (25th August 2018) Authors: Gordon, Kenneth B; Strober, Bruce; Lebwohl, Mark; Augustin, Matthias; Blauvelt, Andrew; Poulin, Yves; Papp, Kim A; Sofen, Howard; Puig, Lluís; Foley, Peter; Ohtsuki, Mamitaro; Flack, Mary; Geng, Ziqian; Gu, Yihua; Valdes, Joaquin M; Thompson, Elizabeth H Z; Bachelez, Hervé Journal: Lancet Issue: Volume 392:Issue 10148(2018) Page Start: 650 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Issue 10198 (17th August 2019) Authors: Reich, Kristian; Gooderham, Melinda; Thaçi, Diamant; Crowley, Jeffrey J; Ryan, Caitriona; Krueger, James G; Tsai, Tsen-Fang; Flack, Mary; Gu, Yihua; Williams, David A; Thompson, Elizabeth H Z; Paul, Carle Journal: Lancet Issue: Volume 394:Issue 10198(2019) Page Start: 576 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers. Issue 4 (20th November 2020) Authors: Litzenburger, Tobias; Steffgen, Jürgen; Benediktus, Ewald; Müller, Fabian; Schultz, Armin; Klein, Elliott; Ramanujam, Meera; Harcken, Christian; Gupta, Alpana; Wu, Jing; Wiebe, Sabrina; Li, Xiujiang; Flack, Mary; Padula, Steven J.; Visvanathan, Sudha; Hünnemeyer, Andreas; Hui, Jianan Journal: British journal of clinical pharmacology Issue: Volume 87:Issue 4(2021) Page Start: 1824 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗